Oruka Therapeutics, Inc. (ORKA:NASDAQ) closed at $80.15 on October 23, 2026, down 1.23% on the day. The stock trades 30.6% below its 52-week high of $115.52 and 217.7% above its 52-week low of $25.23. Over the past year, it gained 194.1%. Oruka Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, ORKA closed higher on 133 days (53%). Its best day was March 13, 2026 (+25.04%) and its worst was July 2, 2026 (-8.66%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Find more stocks like ORKA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.